Selective phosphodiesterase-5 inhibition reduces neointimal hyperplasia in rat carotid arteries after surgical endarterectomy

Journal of Thoracic and Cardiovascular Surgery

Volumn 137, Issue 6, 2009, Pages 1508-1514

  Hirschberg, Kristóf ^a,b   Radovits, Tamás ^a,b   Loganathan, Sivakkanan ^a   Entz, László ^b   Beller, Carsten J ^a   Gross, Marie Luise ^a   Sandner, Peter ^c   Karck, Matthias ^a   Szabó, Gábor ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c BAYER PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CYCLIC GMP; EOSIN; HEMATOXYLIN; PHOSPHODIESTERASE V; TRANSFORMING GROWTH FACTOR BETA1; VARDENAFIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CAROTID ENDARTERECTOMY; COMMON CAROTID ARTERY; CONTROLLED STUDY; DRUG INHIBITION; ENZYME IMMUNOASSAY; ENZYME INHIBITION; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; MALE; MICROSCOPY; NONHUMAN; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION;

ACTINS; ANIMALS; CAROTID ARTERY, COMMON; CAROTID STENOSIS; CYCLIC GMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; ENDARTERECTOMY, CAROTID; HYPERPLASIA; IMIDAZOLES; IMMUNOHISTOCHEMISTRY; MALE; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; RATS; RATS, SPRAGUE-DAWLEY; RECURRENCE; SULFONES; TRANSFORMING GROWTH FACTOR BETA1; TRIAZINES; TUNICA INTIMA;

EID: 67349190578     PISSN: 00225223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jtcvs.2008.10.016     Document Type: Article

References (30)

1. North American Symptomatic Carotid Endarterectomy Trial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med 325 (1991) 445-453
2. Szeplaki G., Hirschberg K., Gombos T., Varga L., Prohaszka Z., Dosa E., et al. Early complement activation follows eversion carotid endarterectomy and correlates with the time of clamping of the carotid artery. Mol Immunol 11 (2008) 3289-3294
3. Szabo A., Laki J., Madsen H.O., Dosa E., Prohaszka Z., Rugonfalvi-Kiss S., et al. Early rise in serum VEGF and PDGF levels predisposes patients with a normal MBL2 genotype to restenosis after eversion endarterectomy. Stroke 38 (2007) 2247-2253
4. Dosa E., Szabo A., Prohaszka Z., Karadi I., Rugonfalvi-Kiss S., Apor A., et al. Changes in the plasma concentration of soluble thrombomodulin in patients with severe carotid artery stenosis after eversion endarterectomy. Inflamm Res 54 (2005) 289-294
5. Hunter G.C., Edgar J., Poth Memorial/W.L. Gore and Associates, Inc, and Lectureship. The clinical and pathological spectrum of recurrent carotid stenosis. Am J Surg 174 (1997) 583-588
6. Ohwada T., Ishibashi T., Yaoita H., Shindo J., Noji H., Ohkawara H., et al. Different contribution of apoptosis to the antiproliferative effects of L-arginine, enalapril and losartan on neointimal growth inhibition after balloon arterial injury. Circ J 66 (2002) 965-971
7. Beller C.J., Radovits T., Kosse J., Gero D., Szabo C., and Szabo G. Activation of the peroxynitrite-poly(adenosine diphosphate-ribose) polymerase pathway during neointima proliferation: a new target to prevent restenosis after endarterectomy. J Vasc Surg 43 (2006) 824-830
8. Melichar V.O., Behr-Roussel D., Zabel U., Uttenthal L.O., Rodrigo J., Rupin A., et al. Reduced cGMP signaling associated with neointimal proliferation and vascular dysfunction in late-stage atherosclerosis. Proc Natl Acad Sci U S A 101 (2004) 16671-16676
9. Yoon J.H., Wu C.J., Homme J., Tuch R.J., Wolff R.G., Topol E.J., et al. Local delivery of nitric oxide from an eluting stent to inhibit neointimal thickening in a porcine coronary injury model. Yonsei Med J 43 (2002) 242-251
10. Pearce C.G., Najjar S.F., Kapadia M.R., Murar J., Eng J., Lyle B., et al. Beneficial effect of a short-acting NO donor for the prevention of neointimal hyperplasia. Free Radic Biol Med 44 (2008) 73-81
11. Janssens S., Flaherty D., Nong Z., Varenne O., van Pelt N., Haustermans C., et al. Human endothelial nitric oxide synthase gene transfer inhibits vascular smooth muscle cell proliferation and neointima formation after balloon injury in rats. Circulation 97 (1998) 1274-1281
12. Liu Y.N., Pan S.L., Peng C.Y., Guh J.H., Huang D.M., Chang Y.L., et al. YC-1 [3-(5′-hydroxymethyl-2′-furyl)-1-benzyl indazole] inhibits neointima formation in balloon-injured rat carotid through suppression of expressions and activities of matrix metalloproteinases 2 and 9. J Pharmacol Exp Ther 316 (2006) 35-41
13. Tulis D.A., Durante W., Peyton K.J., Chapman G.B., Evans A.J., and Schafer A.I. YC-1, a benzyl indazole derivative, stimulates vascular cGMP and inhibits neointima formation. Biochem Biophys Res Commun 279 (2000) 646-652
14. Yamamoto K., Onoda K., Sawada Y., Fujinaga K., Imanaka-Yoshida K., Yoshida T., et al. Locally applied cilostazol suppresses neointimal hyperplasia and medial thickening in a vein graft model. Ann Thorac Cardiovasc Surg 13 (2007) 322-330
15. Beller C.J., Kosse J., Radovits T., Krempien R., Gross M.L., Berger I., et al. Adjunct brachytherapy: a new concept to prevent intimal hyperplasia after surgical endarterectomy?. Eur J Cardiothorac Surg 29 (2006) 334-342
16. Legan E., and Sisson J.A. Method to denude rat aortic endothelium with saponin for phosphoinositide analysis in vascular smooth muscle. J Pharmacol Methods 23 (1990) 31-39
17. Filippi S., Morelli A., Sandner P., Fibbi B., Mancina R., Marini M., et al. Characterization and functional role of androgen-dependent PDE5 activity in the bladder. Endocrinology 148 (2007) 1019-1029
18. Ehsan A., Sommer F., Schmidt A., Klotz T., Koslowski J., Niggemann S., et al. Nitric oxide pathways in human bladder carcinoma. The distribution of nitric oxide synthases, soluble guanylyl cyclase, cyclic guanosine monophosphate, and nitrotyrosine. Cancer 95 (2002) 2293-2301
19. Beller C.J., Kosse J., Radovits T., Gero D., Krempien R., Gross M.L., et al. Poly(ADP-ribose) polymerase inhibition combined with irradiation: a dual treatment concept to prevent neointimal hyperplasia after endarterectomy. Int J Radiat Oncol Biol Phys 66 (2006) 867-875
20. Munzel T., Feil R., Mulsch A., Lohmann S.M., Hofmann F., and Walter U. Physiology and pathophysiology of vascular signaling controlled by guanosine 3′,5′-cyclic monophosphate-dependent protein kinase [corrected Circulation 2008;108:3165]. Circulation 108 (2003) 2172-2183
21. Yu S.M., Hung L.M., and Lin C.C. cGMP-elevating agents suppress proliferation of vascular smooth muscle cells by inhibiting the activation of epidermal growth factor signaling pathway. Circulation 95 (1997) 1269-1277
22. Sinnaeve P., Chiche J.D., Gillijns H., Van Pelt N., Wirthlin D., Van De Werf F., et al. Overexpression of a constitutively active protein kinase G mutant reduces neointima formation and in-stent restenosis. Circulation 105 (2002) 2911-2916
23. Sinnaeve P., Chiche J.D., Nong Z., Varenne O., Van Pelt N., Gillijns H., et al. Soluble guanylate cyclase alpha(1) and beta(1) gene transfer increases NO responsiveness and reduces neointima formation after balloon injury in rats via antiproliferative and antimigratory effects. Circ Res 88 (2001) 103-109
24. Fukumoto S., Koyama H., Hosoi M., Yamakawa K., Tanaka S., Morii H., et al. Distinct role of cAMP and cGMP in the cell cycle control of vascular smooth muscle cells: cGMP delays cell cycle transition through suppression of cyclin D1 and cyclin-dependent kinase 4 activation. Circ Res 85 (1999) 985-991
25. Fu K., Corbley M.J., Sun L., Friedman J.E., Shan F., Papadatos J.L., et al. SM16, an orally active TGF-beta type I receptor inhibitor prevents myofibroblast induction and vascular fibrosis in the rat carotid injury model. Arterioscler Thromb Vasc Biol 28 (2008) 665-671
26. Wolf Y.G., Rasmussen L.M., and Ruoslahti E. Antibodies against transforming growth factor-beta 1 suppress intimal hyperplasia in a rat model. J Clin Invest 93 (1994) 1172-1178
27. Saura M., Zaragoza C., Herranz B., Griera M., Diez-Marques L., Rodriguez-Puyol D., et al. Nitric oxide regulates transforming growth factor-beta signaling in endothelial cells. Circ Res 97 (2005) 1115-1123
28. Wang S., Wu X., Lincoln T.M., and Murphy-Ullrich J.E. Expression of constitutively active cGMP-dependent protein kinase prevents glucose stimulation of thrombospondin 1 expression and TGF-beta activity. Diabetes 52 (2003) 2144-2150
29. Gurjar M.V., Sharma R.V., and Bhalla R.C. eNOS gene transfer inhibits smooth muscle cell migration and MMP-2 and MMP-9 activity. Arterioscler Thromb Vasc Biol 19 (1999) 2871-2877
30. Chiche J.D., Schlutsmeyer S.M., Bloch D.B., de la Monte S.M., Roberts Jr. J.D., Filippov G., et al. Adenovirus-mediated gene transfer of cGMP-dependent protein kinase increases the sensitivity of cultured vascular smooth muscle cells to the antiproliferative and pro-apoptotic effects of nitric oxide/cGMP. J Biol Chem 273 (1998) 34263-34271